Lack of association between α2B-adrenergic receptor polymorphism and risk of restenosis following coronary angioplasty and stent implantation - Preliminary report

Clinical Chemistry and Laboratory Medicine

Volumn 44, Issue 7, 2006, Pages 807-812

  Manolis, Antonis S ^a   Patsouras, Nikolaos ^b   Ilias, Ioannis ^c   Constantakopoulos, John ^c   Pyriohou, Anastasia ^c   Lymperopoulos, Anastasios ^c   Spathas, Dionysios H ^c   Flordellis, Christodoulos S ^c  

^a EVANGELISMOS HOSPITAL   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^c UNIVERSITY OF PATRAS   (Greece)

Author keywords

2B adrenergic receptor; Coronary heart disease; Polymorphisms; Restenosis

Indexed keywords

ALPHA 2B ADRENERGIC RECEPTOR; ADRENERGIC RECEPTOR ALPHA 2B; ADRENERGIC RECEPTOR ALPHA-2B; ALPHA 2 ADRENERGIC RECEPTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY STENT; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENE DELETION; GENE FREQUENCY; GENE INSERTION SEQUENCE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; ANGIOPLASTY; CORONARY ARTERY DISEASE; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; PATHOLOGY; RISK FACTOR; STENT;

ADULT; AGED; ANGIOPLASTY; CORONARY DISEASE; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, ALPHA-2; RISK FACTORS; STENTS;

EID: 33745202048     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2006.155     Document Type: Article

References (54)

1. Anderson HV. Restenosis after coronary angioplasty. Dis Mon 1993;39:613-70.
2. Bauters C, Hamon M, Van Belle E, Dupuis B, Lablanche JM, Bertrand ME. Restenose apres angioplastie coronaire. Apport des modeles experimentaux. Arch Mal Coeur Vaiss 1993;86(Spec 1):47-56.
3. Schwartz SM, de Blois D, O'Brien ER. The intima: soil for atherosclerosis and restenosis. Circ Res 1995;77:445-65.
4. Angerio AD, Fink DA. New strategies in the prevention of restenosis. Crit Care Nurs 2001;24:62-8.
5. Richman JG, Regan JW. Alpha 2-adrenergic receptors increase cell migration and decrease F-actin labeling in rat aortic smooth muscle cells. Am J Physiol 1998;274:654-62.
6. Faber JE, Yang N, Xin X. Expression of alpha-adrenoreceptor subtypes by smooth muscle cells and fibroblasts in rat aorta and in cell culture. J Pharmacol Exp Ther 2001;298:441-52.
7. Limbird LE. Synergies at the synapse. Br J Pharmacol 2003;138:1387-8.
8. Heusch G. Alpha-adrenergic mechanisms in myocardial ischemia. Circulation 1990;81:1-13.
9. Gavras H. Adrenergic receptors in hypertension and heart failure. Am J Hypertens 2004;17:98-9.
10. Lorenz W, Lomansey JW, Collins S, Regan JW, Caron MG, Lefkowitz RJ. Expression of three alpha 2-adrenergic receptor subtypes in rat tissues: implications for alpha2-receptor classification. Mol Pharmacol 1990;38:599-603.
11. Bylund DB. Subtypes of alphal- and alpha2-adrenergic receptors. FASEB J 1992;6:832-9.
12. i coupling. J Biol Chem 2000;275:38518-23.
13. Small KM, Forbes SL, Rahman FF, Bridges KM, Liggett SB. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem 2000;275:23059-64.
14. Small KM, Brown KM, Forbes SL, Liggett SB. Polymorphic deletion of three intracellular acidic residues of the alpha2B-adrenergic receptor decreases G protein-coupled receptor kinase-mediated phosphorylation and desensitization. J Biol Chem 2001;276:4917-22.
15. Altman JD, Trendelenburg AU, MacMillan L, Bernstein D, Limbird L, Starke K, et al. Abnormal regulation of the sympathetic nervous system in alpha2A-adrenergic receptor knockout mice. Mol Pharmacol 1999;56:154-61.
16. Sallinen J, Link RE, Haapalinna A, Viitamaa T, Kulatunga M, Sjoholm B, et al. Genetic alteration of alpha 2C-adrenoreceptor expression in mice: influence on locomotor, hypothermic and neurochemical effects of dexmedetomidine, a subtype-nonselective alpha 2-adrenoreceptor agonist. Mol Pharmacol 1997;51:36-46.
17. Sallinen J, Haapalinna A, MacDonald E, Viitamaa T, Lahdesmaki J, Rybnikova E, et al. Genetic alteration of the alpha2-adrenoreceptor subtype c in mice affects the development of behavioural despair and stress-induced increases in plasma corticosterone levels. Mol Psychiatry 1999;4:443-52.
18. Heinonen P, Koulu M, Pesonen U, Karvonen MK, Rissanen A, Laakso M, et al. Identification of three-amino acid deletion in the alpha 2B-adrenergic receptor that is associated with reduced basal metabolic rate in obese subjects. J Clin Endocrinol Metab 1999;84:2429-33.
19. Snapir A, Heinonen P, Tuomainen TP, Alhopuro P, Karvonen MK, Lakka TA, et al. An insertion/deletion polymorphism in the alpha 2B-adrenergic receptor gene is a novel genetic risk factor for acute coronary disease. J Am Coll Cardiol 2001;37:1516-22.
20. Heinonen P, Jartti L, Jarvisalo MJ, Pesonen U, Kaprio JA, Ronnemaa T, et al. Deletion polymorphism in the alpha2B-adrenergic receptor gene is associated with flow-mediated dilatation of the brachial artery. Clin Sci (Lond) 2002;103:517-24.
21. Snapir A, Koskenvuo J, Toikka J, Orho-Melander M, Hinkka S, Saraste M, et al. Effects of common polymorphisms in the alpha1A, alpha2B, betal, beta2 adrenoceptors on haemodynamic responses to adrenaline. Clin Sci (Lond) 2003;104:509-20.
22. Suzuki N, Matsunaga T, Nagasumi K, Yamamura T, Shihara N, Moritani T, et al. Alpha(2B)-adrenergic receptor deletion polymorphism associates with autonomic nervous system activity in young healthy Japanese. J Clin Endocrinol Metab 2003;88:1184-7.
23. Snapir A, Mikkelsson J, Perola M, Penttila A, Scheinin M, Karhunen PJ. Variation in the alpha2B-adrenoceptor gene as a risk factor for prehospital fatal myocardial infarction and sudden cardiac death. J Am Coll Cardiol 2003;41:190-4.
24. National Cholesterol Education Program, ATP III Guidelines At-a-Glance Quick Desk Reference, NIH Publication No. 01-3305. US Department of Health and Human Services, Public Health Service, http://www.nhlbi.nih.gov/guidelines/ cholesterol/atglance.pdf. Accessed on December 13, 2005.
25. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2005;28:S37-42.
26. Schomig A, Kastrati A, Mudra H, Blasini R, Schuhlen H, Klauss V, et al. Four-year experience with Palmaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure. Circulation 1994;90:2716-24.
27. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9.
28. Manolis AS, Chiladakis J, Hahalis G, Agelopoulos G. Initial experience with a newer generation coronary stent. J Invest Cardiol 2001;13:217-22.
29. Manolis AS. Reduced incidence of clinical restenosis with newer generation stents, stent oversizing and high-pressure deployment: single-operator experience. Clin Cardiol 2001;24:119-26.
30. Holmes DR. State of the art in coronary intervention. Am J Cardiol 2003;91:50A-3A.
31. Manolis AS, Tzeis S, Andrikopoulos G, Koulouris S, Melita H. Aspirin and clopidogrel: a sweeping combination in cardiology. Curr Med Chem Cardiovasc Hematol Agents 2005;3:203-19.
32. Guo SW, Thompson EA. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 1992;48:361-72.
33. Kaplan NM, Gidding SS, Pickering TG, Wright JT. Task Force 5: systemic hypertension. J Am Coll Cardiol 2005;45:1346-8.
34. Kastrati A, Dirschinger J, Schomig A. Genetic risk factors and restenosis after percutaneous coronary interventions. Herz 2000;25:34-46.
35. Casterella PJ, Teirstein PS. Prevention of coronary restenosis. Cardiol Rev 1999;7:219-31.
36. Hamon M, Amant C, Bauters C, Richard F, Helbecque N, Passard F, et al. Dual determination of angiotensin-converting enzyme and angiotensin-II type 1 receptor genotypes as predictors of restenosis after coronary angioplasty. Am J Cardiol 1998;81:79-81.
37. Zee RY, Fernandez-Otiz A, Macaya C, Pintor E, Lindpaintner K, Fernandez-Cruz A. Lipid metabolism and occurrence of post-percutaneous transluminal coronary angioplasty restenosis: role of cholesteryl ester transfer protein and paraoxonase/arylesterase. J Thromb Haemost 2003;1:1202-7.
38. Violaris AG, Thury A, Regar E, Melkert R, Serruys PW. Influence of a history of smoking on short-term (six month) clinical and angiographic outcome after successful coronary angioplasty. Heart 2000;84:229-306.
39. Gurlek A, Dagalp Z, Oral D, Omurlu K, Erol C, Akyol T, et al. Restenosis after transluminal coronary angioplasty: a risk factor analysis. J Cardiovasc Risk 1995;2:51-5.
40. Kumbasar SD, Dincer I, Ertas F, Gulec S, Erol C, Akyurek O, et al. Hyperhomocysteinemia and restenosis. J Cardiovasc Risk 2001;8:9-13.
41. Johansen O, Abdelnoor M, Brekke M, Seljeflot M, Hostmark AT, Arnesen H. Predictors of restenosis after coronary angioplasty. A study on demographic and metabolic variables. Scand Cardiovasc J 2001;35:86-91.
42. Cooke T, Sheahan R, Foley D, Reilly M, D'Arcy G, Jauch W, et al. Lipoprotein(a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease. Circulation 1994;89:1593-8.
43. Mazeika P, Prasad N, Bui S, Seidelin PH. Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. Am Heart J 2003;145:1013-21.
44. Heper G. The comparison of different clinical, laboratory, and angiographical parameters in diabetic stent restenosis. Heart Dis 2002;4:139-40.
45. Hayashida K, Tanaka M, Morita H. Chlamydia pneumoniae seropositivity predicts the risk of restenosis after percutaneous transluminal coronary angioplasty. Heart Vessels 2002;16:137-45.
46. George J, Harats D, Bakshi E, Adler Y, Levy Y, Gilburd B, et al. Anti-oxidized low density lipoprotein antibody determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty. Immunol Lett 1999;68:263-6.
47. Roller RE, Schnedl WJ, Korniger C. Predicting the risk of restenosis after angioplasty in patients with peripheral arterial disease. Clin Lab 2001;47:555-9.
48. Zee RY, Hoh J, Cheng S, Reynolds R, Grow MA, Silbergleit A, et al. Multi-locus interactions predict risk for post-PTCA restenosis: an approach to the genetic analysis of common disease. Pharmacogenomics J 2002;2:197-201.
49. Fraeyman N, Vanscheeuwijck P, Wang JM, Huang Y, De Potter WP, Regan JW. Changes in the expression of alpha(2)-adrenergic receptor subtypes during maturation of neuronal cells from fetal pig superior cervical ganglia. Brain Res Dev Brain Res 1999;116:127-32.
50. Suzuki T, Okumura K, Sone T, Kosokabe T, Tsuboi H, Kondo J, et al. The Glu298Asp polymorphism in endothelial nitric oxide synthase gene is associated with coronary in-stent restenosis. Int J Cardiol 2002;86:71-6.
51. Ferrero V, Ribichini F, Matullo G, Guarrera S, Carturan S, Vado A, et al. Estrogen receptor-alpha polymorphisms and angiographic outcome after coronary artery stenting. Arterioscler Thromb Vasc Biol 2003;23:2223-8.
52. Exner M, Schillinger M, Minar E, Mlekusch W, Schlerka G, Haumer M, et al. Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with restenosis after percutaneous transluminal angioplasty. J Endovasc Ther 2001;8:433-40.
53. Small KM, Liggett SB. Identification and functional characterization of alpha2-adrenoreceptor polymorphisms. Trends Pharmacol Sci 2001;22:471-7.
54. Sykiotis GP, Polyzogopoulou E, Georgopoulos NA, Trakada G, Spyropoulos K, Kalfarentzos F, et al. The alpha2B adrenergic receptor deletion/insertion polymorphism in morbid obesity. Clin Auton Res 2003;13:203-7.